Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation JOURNAL OF NEUROIMMUNOLOGY Kraus, A., Race, B., Phillips, K., Winkler, C., Saturday, G., Kurnellas, M., Rothbard, J. B., Groveman, B. R., Steinman, L., Caughey, B. 2016; 298: 42-50

Abstract

Amyloid hexapeptide molecules are effective in the treatment of the murine model of neuroinflammation, known as experimental autoimmune encephalomyelitis (EAE). Efficacy however differs between two inbred mouse strains, C57BL/6J (B6) and C57BL/10SnJ (B10). Amyloid hexapeptide treatments improved the clinical outcomes of B6, but not B10 mice, indicating that genetic background influences therapeutic efficacy. Moreover, although previous studies indicated that prion protein deficiency results in more severe EAE in B6 mice, we observed no such effect in B10 mice. In addition, we found that amyloid hexapeptide treatments of B10 and B6 mice elicited differential IL4 responses. Thus, the modulatory potential of prion protein and related treatments with other amyloid hexapeptides in EAE depends on mouse strain.

View details for DOI 10.1016/j.jneuroim.2016.06.010

View details for Web of Science ID 000383936600007

View details for PubMedID 27609274